Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in
Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy …

Recognizing the importance of timely guidance regarding the rapidly evolving field of
hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) …

The treatment of chronic hepatitis C (HCV) in human immunodeficiency virus 1 (HIV)–
infected individuals has been historically marked by low sustained virologic response (SVR) …

Recognizing the importance of timely guidance regarding the rapidly evolving field of
hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

We evaluated treatment outcomes in a prospective registry of human immunodeficiency
virus/hepatitis C virus (HCV)–coinfected patients treated with interferon‐free direct‐acting …

Combination direct-acting antiviral therapy of 8–24 weeks is highly effective for the treatment
of chronic hepatitis C infection. However, shortening the treatment duration to less than 8 …

Background: HCV treatment showed dramatical change due to the introduction of potent,
strong, direct antiviral drugs. Before the appearance of Direct-acting antivirals, multiple …

Guidelines on the management of hepatitis C were first developed in 2004 and revised in
2013 and 2015 by the Korean Association for the Study of the Liver (KASL). Recently …

Sofosbuvir and ribavirin exert their anti-hepatitis C virus (anti-HCV) activity following
metabolic activation in the liver. However, intrahepatic concentrations of the …